Regeneron Pharmaceuticals Inc
REGN
Company Profile
Business description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Contact
777 Old Saw Mill River Road
TarrytownNY10591-6707
USAT: +1 914 847-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15,410
Regeneron Pharmaceuticals Inc News & Analysis
stocks
Contenders in the vaccine race
These stocks could benefit from the race to roll out antibody therapy for covid-19, writes Vikram Barhat.
stocks
Three vaccines capable of US authorisation in 2020
We expect most US adults will be vaccinated in the first half of 2021, writes Morningstar healthcare strategist Karen Andersen.
markets
What a Covid-19 vaccine means for investors
Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,860.10 | 24.60 | -0.28% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,644.28 | 182.60 | 0.36% |
| FTSE 100 | 10,505.01 | 13.62 | 0.13% |
| HKSE | 24,808.06 | 520.17 | -2.05% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 65,039.78 | 40.37 | 0.06% |
| NZX 50 Index | 13,240.00 | 12.19 | 0.09% |
| S&P 500 | 7,520.36 | 1.24 | 0.02% |
| S&P/ASX 200 | 8,632.40 | 22.10 | -0.26% |
| SSE Composite Index | 4,068.92 | 24.81 | -0.61% |